Pfizer Rakes in Billions on COVID-19 Vaccine Sales, Highest Revenue in Company’s History

Vaccine maker Pfizer Reports record revenue for 2022. COVID-19 Even though products account for a large portion of sales, the company is still facing backlash because it claims to be. “mutate” There are many viruses and doctors are refusing to prescribe boosters.

For 2022, full-year revenues were $100.3 billion. “all-time high” According to the earnings, multinational corporations Release January 31, 2017, by Pfizer This marks the company’s first year of exceeding $100 billion in annual sales. Revenues reflect a 30% operational growth. Revenues grew only 2 percent in terms of operational growth, excluding contributions from COVID-19 products and Paxlovid Antiviral. These two products together generated more than $56 billion in sales.

The year “2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history,” Dr. Albert Bourla is chairman and CEO at Pfizer.

“As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.”

The sales of Paxlovid and Comirnaty are expected to drop to their lowest level in 2023, before rebounding to growth next year. “due to significant government supply on hand” The company stated that the announcement was made at the start of the year.

Pfizer estimates that Comirnaty sales will fall by 64 percent to $13.5 billion, while Paxlovid sales will drop 58 percent to $8 billion.

Mutating Virus, Quadrupling Vaccine Price

Pfizer’s results come as the company is under scrutiny following an investigative report which revealed that the firm is considering mutating the COVID-19 virus for developing new vaccines against it.

“One of the things we’re exploring is like, why don’t we just mutate it ourselves so we could create—preemptively develop new vaccines, right?” Dr. Jordon Walk, director of research and innovation at Pfizer. Submitted Project Veritas undercover reporter

“If we’re going to do that, though, there’s a risk of like, as you could imagine—no one wants to be having a pharmaceutical company mutating [expletive] viruses.” Walker stated that COVID-19 would be “a cash cow for us for a while going forward.”

Sen. Ron Johnson (R. Wis.) called for Congress to investigate COVID-19’s approval process. Sen. Marco Rubio (R-Fla.) sent a letter to Bourla asking for more information about Pfizer’s efforts to mutate the COVID-19 virus.

Pfizer will begin selling the Comirnaty COVID-19 vaccination through the United States commercial channels during the second half this year. This is a departure from the earlier practice of selling to government. In 2023, the firm plans to increase the price of the vaccine about four times.

European Parliament Ban, Lack of Vaccine Data

Pfizer advocates for increased COVID-19 vaccinations. However, doctors are increasingly reluctant to get booster jabs due to lack of evidence from clinical trials.

“I have taken my last COVID vaccine without RCT level evidence,” McGill University’s infectious disease expert, Dr. Todd Lee, has recently been featured in Write Follow us on Twitter. He was pointing out the absence of randomized clinical trials (RCTs), for booster vaccines.

“Pay close attention to note this isn’t anti-vaccine sentiment. This is ‘provide [hard] evidence of benefit to justify ongoing use’ which is very different. It is only fair for a $30 billion a year product given to hundreds of millions,” Lee stated that he has had three doses of vaccines.

Meanwhile, Pfizer officials are facing a potential ban from the European Parliament due to the company’s lack of transparency regarding COVID-19 vaccine purchase agreements during the pandemic.

On Jan. 11, the European Parliament’s committee on COVID approved the ban proposal. The ban was approved by all political parties, except two.

*As an Amazon Associate I earn from qualifying purchases